Clobetasol-loaded nanostructured lipid carriers for epidermal targeting

Silva, Luís Antônio Dantas; Andrade, Lígia Marquez; Sá, Fernando Augusto Pires de; Marreto, Ricardo Neves; Lima, Eliana Martins; Gratieri, Taís; Taveira, Stephânia Fleury

doi:10.1111/jphp.12543

Cited by 48 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Formulations showed no micrometric clusters, even those containing the cationic polymer. Such finding contributes to the hypothesis by which the interaction between cationic polymer and anionic nanoparticles occurred as a coating process, leaving a homogeneously dispersed system, as also observed by Silva et al …”

Section: Resultsmentioning

confidence: 93%

“…Some studies have indeed reported the production of coated nanosystems by adding the polymer in the nanoparticle aqueous dispersion . In a previous study, we observed a nanoparticle increase from 124.56 to 257.5 nm after Ch coating . In this study, the percentage of Ch added to the system was higher, as the intention was to increase the viscosity rather than alter the own nanosystem.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers

Venâncio

Andrade

Esteves

et al. 2017

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers

Venâncio

Andrade

Esteves

et al. 2017

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Examples include a ciclopirox nail lacquer with a water-soluble hydroxypropyl chitosan base (Onytec) 43 and econazole liposomal formulation (Pevaryl cream and generics). 44 In addition to the technologies described above, there are others that can be applied to dermatologic antifungal drug products to improve their effectiveness, 45 such as physical methods to promote drug permeation or accumulation, as iontophoresis 46 and microneedles 47 or formulation modifications as liposomal preparations, 48 which enhance skin deposition, nanostructured lipid carriers that can direct the drug to specific skin layers, 49,50 chitosan nanoparticles that provide an increased interval between product administrations, 51 and solid lipid nanoparticles and nanostructured lipid carriers that enhance nail hydration and drug penetration into the nail plate in onychomicosis treatments. 4 Thus, there is a clear space for development of better and novel topical antifungal products in both countries.…”

Section: Discussionmentioning

confidence: 99%

Regulatory Requirements and Innovation: A Comparison of the Dermatologic Antifungal Drug Product Markets in Brazil and United States

Kollross¹,

Cunha-Filho

Gelfuso

2019

Ther Innov Regul Sci

Self Cite

View full text Add to dashboard Cite

Background: Development of novel dermatological topical products for the treatment of cutaneous fungal infections is a constant necessity, especially in developing countries. Through public health policies, many developing countries have facilitated in the last decades the entry of generic products, which can be superficially seen as a threat to innovation. To verify whether regulatory requirements, or the waiving of some requirements, could have an impact on innovation, we performed a detailed technical comparison of the dermatologic antifungal markets of Brazil and of the United States, taking Brazil as an example of a developing country with more lenient requirements regarding the registration of generic topical drug products. Methods: The official databank of ANVISA (DATAVISA) and of US Food and Drug Administration (Orange Book) were assessed for valid topical dermatological antifungal drug products registered. Results: The Brazilian market has a greater number of registered drug products encompassing a greater variety of drug substances than the US, but the latter comprises more products with novel technologies. In both countries, cream was the predominant dosage form and imidazoles were the major substance group. Ketoconazole was the lead active substance in Brazil and ciclopirox was the lead drug in the US. Generic products dominated both markets. Conclusions: Despite the great number of registered products, the Brazilian market lacks the latest technologies, reflecting that the ease of generics registration is not accompanied by innovation.

show abstract

“…Hybridization enables the development of smart formulations or pharmaceutical forms that are able to specifically interact with biological barriers, 17 such as the mucosal tissues and skin. There are some reports of lipid-biopolymer hydrogels for the topical sustained release of ibuprofen, 18 ketoprofen, 19 ofloxacin, 20 Resina draconis, 21 clobetasol, 22 and LAs, [23][24][25] which exhibited optimized properties in comparison to their lipid-related DDS.…”

Section: Introductionmentioning

confidence: 99%

Nanohybrid hydrogels designed for transbuccal anesthesia

Ribeiro

Franz-Montan

Breitkreitz

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundLocal anesthesia in dentistry is by far the most terrifying procedure for patients, causing treatment interruption. None of the commercially available topical formulations is effective in eliminating the pain and phobia associated to the needle insertion and injection.Materials and methodsIn this work we prepared a nanostructured lipid-biopolymer hydrogel for the sustained delivery of lidocaine–prilocaine (LDC-PLC) for transbuccal pre-anesthesia. The lipid was composed of optimized nanostructured lipid carriers (NLC) loaded with 5% LDC-PLC (NLC/LDC-PLC). The biopolymer counterpart was selected among alginate, xanthan (XAN), and chitosan matrices. The XAN-NLC hydrogel presented the most uniform aspect and pseudoplastic rheological profile, as required for topical use; therefore, it was selected for subsequent analyses. Accelerated stability tests under critical conditions (40°C; 75% relative humidity) were conducted for 6 months, in terms of drug content (mg/g), weight loss (%), and pH.ResultsIn vitro LDC-PLC release profile through Franz diffusion cells revealed a bimodal kinetics with a burst effect followed by the sustained release of both anesthetics, for 24 hours. Structural analyses (fourier transform infrared spectroscopy, differential scanning calorimetry and scanning electron microscopy) gave details on the molecular organization of the hybrid hydrogel, confirming the synergic interaction between the components. Safety and efficacy were evaluated through in vitro cell viability (3T3, HaCat, and VERO cells) and in vivo antinociceptive (tail-flick, in mice) tests, respectively. In comparison to a control hydrogel and the eutectic mixture of 5% LDC-PLC cream (EMLA®), the XAN-NLC/LDC-PLC hybrid hydrogel doubled and quadrupled the anesthetic effect (8 hours), respectively.ConclusionConsidering such exciting results, this multifaceted nanohybrid system is now ready to be further tested in clinical trials.

show abstract

Clobetasol-loaded nanostructured lipid carriers for epidermal targeting

Abstract: NLC proved to be a system with potential for targeting drug delivery to the epidermal layer.

Cited by 48 publications

References 34 publications

Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers

Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers

Regulatory Requirements and Innovation: A Comparison of the Dermatologic Antifungal Drug Product Markets in Brazil and United States

Nanohybrid hydrogels designed for transbuccal anesthesia

Contact Info

Product

Resources

About